FDA questions use of aspirin for primary prevention of stroke and heart attackBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g3168 (Published 08 May 2014) Cite this as: BMJ 2014;348:g3168
View Full Text
- Michael McCarthy
Aspirin should not be routinely used for the primary prevention of heart attack or stroke in patients with no history of cardiovascular disease, the US Food and Drug Administration has concluded.
“The FDA has reviewed the available data and does not believe the evidence supports the general use of aspirin for primary prevention of a heart attack or stroke,” it said in a statement posted online last week.1
“In fact, there are serious risks associated with the use of aspirin, including increased …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.